-
What Pigs Revealed that Mice Missed in Huntington’s Disease
9 min read
Latest News
-
Exciting new Huntingtin lowering tool described
8 min read
Exciting new Huntingtin Lowering work from @SangamoTx and @CHDIfoundation using "Zinc Fingers" to shut down expression of the mutant Huntingtin gene. More details on this exciting new technique here.
-
Details emerge of first Huntington’s disease gene therapy clinical trial
8 min read
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
-
Fresh Updates from First Huntingtin Lowering Study Publication
12 min read
Hot off the presses – New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
-
An Updated Trial Design for Roche's Huntingtin Lowering Trial
8 min read
Roche announces an update to the GENERATION HD1 trial after reviewing the ASO open label extension study
-
When interrupting is good: genetic hiccups that protect against Huntington's disease
12 min read
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
-
Huntington's disease therapeutics conference 2019 – Day 3
12 min read
New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 2
5 min read
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 1
9 min read
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Huntington's disease goes viral as UniQure inches ahead in gene therapy race
9 min read
FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
11 min read
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
